Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L. Pinkerton JV, et al. Among authors: zuurman l. Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3. Menopause. 2024. PMID: 38564691 Clinical Trial.
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Simon JA, et al. Among authors: zuurman l. Menopause. 2023 Mar 1;30(3):239-246. doi: 10.1097/GME.0000000000002138. Epub 2023 Jan 30. Menopause. 2023. PMID: 36720081 Free PMC article. Clinical Trial.
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier JL, van Hasselt JG, Zuurman L, Erwich FA, van Gerven JM. Klumpers LE, et al. Among authors: zuurman l. Br J Clin Pharmacol. 2013 Jul;76(1):65-77. doi: 10.1111/bcp.12071. Br J Clin Pharmacol. 2013. PMID: 23278647 Free PMC article. Clinical Trial.
Involvement of the endocannabinoid system in reward processing in the human brain.
van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuurman L, van Gerven J, Kahn RS, Ramsey NF. van Hell HH, et al. Among authors: zuurman l. Psychopharmacology (Berl). 2012 Feb;219(4):981-90. doi: 10.1007/s00213-011-2428-8. Epub 2011 Aug 6. Psychopharmacology (Berl). 2012. PMID: 21822593 Free PMC article. Clinical Trial.
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM. Krum H, et al. Among authors: zuurman l. Cardiovasc Ther. 2010 Apr;28(2):124-32. doi: 10.1111/j.1755-5922.2010.00146.x. Epub 2010 Feb 23. Cardiovasc Ther. 2010. PMID: 20184589 Free article. Clinical Trial.
Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects.
Jacobs GE, Hulskotte EG, van Gerven JM, Zuurman L, de Kam ML, Elassaiss-Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Burggraaf J. Jacobs GE, et al. Among authors: zuurman l. J Psychopharmacol. 2011 Mar;25(3):353-60. doi: 10.1177/0269881109358203. Epub 2010 Feb 8. J Psychopharmacol. 2011. PMID: 20142306 Clinical Trial.
16 results